VIVUS Company Profile (NASDAQ:VVUS)


VIVUS logoVIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:VVUS
  • CUSIP: 92855110
  • Web:
  • Market Cap: $104.32 million
  • Outstanding Shares: 105,812,000
Average Prices:
  • 50 Day Moving Avg: $0.98
  • 200 Day Moving Avg: $1.09
  • 52 Week Range: $0.86 - $1.47
  • Trailing P/E Ratio: 3.187
  • Foreward P/E Ratio: -2.11
  • P/E Growth: -3.180
Sales & Book Value:
  • Annual Revenue: $133.4 million
  • Price / Sales: 0.75
  • Book Value: $0.05 per share
  • Price / Book: 18.25
  • EBIDTA: $67.14 million
  • Net Margins: 24.72%
  • Return on Equity: 3,746.48%
  • Return on Assets: 11.02%
  • Debt-to-Equity Ratio: 40.25%
  • Current Ratio: 5.51%
  • Quick Ratio: 5.20%
  • Average Volume: 896,919 shs.
  • Beta: 0.88
  • Short Ratio: 9.72

Frequently Asked Questions for VIVUS (NASDAQ:VVUS)

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) issued its earnings results on Thursday, August, 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.20. The business earned $13.77 million during the quarter, compared to the consensus estimate of $19 million. VIVUS had a return on equity of 3,746.48% and a net margin of 24.72%. The company's revenue for the quarter was down 40.1% on a year-over-year basis. During the same period last year, the company earned ($0.19) EPS. View VIVUS's Earnings History.

When will VIVUS make its next earnings announcement?

VIVUS is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for VIVUS.

Are investors shorting VIVUS?

VIVUS saw a decrease in short interest during the month of August. As of August 31st, there was short interest totalling 5,103,560 shares, a decrease of 28.0% from the August 15th total of 7,085,696 shares. Based on an average daily volume of 1,100,513 shares, the days-to-cover ratio is currently 4.6 days. Approximately 5.1% of the company's stock are short sold.

Who are some of VIVUS's key competitors?

Who are VIVUS's key executives?

VIVUS's management team includes the folowing people:

  • David York Norton, Chairman of the Board and Director
  • Seth H. Z. Fischer, Chief Executive Officer, Chief Commercial Officer, Director
  • Mark K. Oki CPA, Chief Financial Officer, Chief Accounting Officer
  • John L. Slebir Esq., Senior Vice President - Business Development, General Counsel, Secretary
  • Guy P. Marsh, Vice President - U.S. Operations, General Manager
  • Johann Noor Mohamed, Vice President, Corporate Controller
  • Wesley W. Day Ph.D., Vice President - Clinical Development
  • Santosh T. Varghese M.D, Vice President-Medical & Regulatory Affairs, Pharmacovigilance, and QA
  • Thomas B. King, Director
  • Herman Rosenman CPA, Director

Who owns VIVUS stock?

VIVUS's stock is owned by many different of institutional and retail investors. Top institutional investors include North Tide Capital LLC (4.73%), Vanguard Group Inc. (3.09%), AJO LP (2.58%), Acadian Asset Management LLC (1.74%), OxFORD Asset Management LLP (0.88%) and Menta Capital LLC (0.27%). Company insiders that own VIVUS stock include John L Slebir, North Tide Capital, Llc and Santosh T Varghese. View Institutional Ownership Trends for VIVUS.

Who sold VIVUS stock? Who is selling VIVUS stock?

VIVUS's stock was sold by a variety of institutional investors in the last quarter, including North Tide Capital LLC, Vanguard Group Inc., Nine Chapters Capital Management LLC, Menta Capital LLC, Royal Bank of Canada and State Street Corp. Company insiders that have sold VIVUS stock in the last year include North Tide Capital, Llc and Santosh T Varghese. View Insider Buying and Selling for VIVUS.

Who bought VIVUS stock? Who is buying VIVUS stock?

VIVUS's stock was bought by a variety of institutional investors in the last quarter, including AJO LP, Acadian Asset Management LLC, OxFORD Asset Management LLP, Spark Investment Management LLC, Russell Investments Group Ltd., Northern Trust Corp, Bank of New York Mellon Corp and IHT Wealth Management LLC. View Insider Buying and Selling for VIVUS.

How do I buy VIVUS stock?

Shares of VIVUS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VIVUS's stock price today?

One share of VIVUS stock can currently be purchased for approximately $0.95.

MarketBeat Community Rating for VIVUS (NASDAQ VVUS)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  472
MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for VIVUS (NASDAQ:VVUS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for VIVUS (NASDAQ:VVUS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/25/2016WallachBeth CapitalSet Price TargetBuy$2.80N/AView Rating Details
5/4/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
3/10/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$4.00 -> $1.00N/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for VIVUS (NASDAQ:VVUS)
Earnings by Quarter for VIVUS (NASDAQ:VVUS)
Earnings History by Quarter for VIVUS (NASDAQ VVUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.13)N/AView Earnings Details
5/3/2017Q1 2017($0.13)($0.01)$27.01 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.23$0.54$48.82 million$81.81 millionViewListenView Earnings Details
11/9/2016Q316($0.19)($0.09)$21.91 million$13.40 millionViewListenView Earnings Details
8/4/2016Q216($0.31)($0.11)$19.00 million$13.77 millionViewN/AView Earnings Details
5/3/2016Q116($0.21)($0.12)$17.97 million$15.32 millionViewN/AView Earnings Details
3/9/2016Q4($0.12)($0.12)$22.90 million$15.34 millionViewN/AView Earnings Details
11/4/2015Q315($0.17)($0.15)$20.24 million$24.90 millionViewN/AView Earnings Details
7/30/2015Q215($0.23)($0.19)$18.76 million$23.00 millionViewListenView Earnings Details
5/5/2015Q115($0.22)($0.15)$21.80 million$32.20 millionViewN/AView Earnings Details
2/24/2015Q414($0.25)($0.25)$20.00 million$21.70 millionViewListenView Earnings Details
11/5/2014Q314($0.25)($0.10)$21.90 million$33.90 millionViewListenView Earnings Details
8/7/2014Q214($0.28)($0.25)$17.90 million$21.90 millionViewListenView Earnings Details
5/5/2014Q114($0.37)($0.15)$11.40 million$36.70 millionViewN/AView Earnings Details
2/24/2014Q413($0.40)($0.17)$28.20 million$44.06 millionViewListenView Earnings Details
11/5/2013Q313($0.38)($0.48)$21.78 million$27.38 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.55)$12.76 million$5.53 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.51)($0.53)$5.22 million$4.10 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.44)($0.56)$3.09 million$1.97 millionViewN/AView Earnings Details
11/6/2012Q312($0.34)($0.40)$0.35 million$0.04 millionViewN/AView Earnings Details
8/7/2012($0.23)($0.24)ViewN/AView Earnings Details
5/7/2012($0.13)($0.20)ViewN/AView Earnings Details
2/28/2012($0.12)($0.14)ViewN/AView Earnings Details
11/7/2011($0.12)($0.10)ViewN/AView Earnings Details
8/1/2011($0.13)($0.20)ViewN/AView Earnings Details
5/2/2011($0.15)($0.12)ViewN/AView Earnings Details
2/28/2011($0.22)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for VIVUS (NASDAQ:VVUS)
Current Year EPS Consensus Estimate: $-0.39 EPS
Next Year EPS Consensus Estimate: $-0.45 EPS


Dividend History for VIVUS (NASDAQ:VVUS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for VIVUS (NASDAQ:VVUS)
Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 35.82%
Insider Trades by Quarter for VIVUS (NASDAQ:VVUS)
Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)
Insider Trades by Quarter for VIVUS (NASDAQ:VVUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/3/2017Santosh T VargheseInsiderSell423$1.23$520.29View SEC Filing  
4/4/2017Santosh T VargheseInsiderSell440$1.08$475.20View SEC Filing  
3/10/2017North Tide Capital, LlcMajor ShareholderSell1,149,400$1.16$1,333,304.00View SEC Filing  
3/7/2017North Tide Capital, LlcMajor ShareholderSell192,800$1.08$208,224.00View SEC Filing  
3/2/2017North Tide Capital, LlcMajor ShareholderSell160,100$1.13$180,913.00View SEC Filing  
2/27/2017North Tide Capital, LlcMajor ShareholderSell333,000$1.14$379,620.00View SEC Filing  
2/22/2017North Tide Capital, LlcMajor ShareholderSell161,800$1.11$179,598.00View SEC Filing  
2/16/2017North Tide Capital, LlcMajor ShareholderSell305,090$1.10$335,599.00View SEC Filing  
2/13/2017North Tide Capital, LlcMajor ShareholderSell176,410$1.11$195,815.10View SEC Filing  
2/8/2017North Tide Capital, LlcMajor ShareholderSell563,527$1.06$597,338.62View SEC Filing  
2/7/2017North Tide Capital, LlcMajor ShareholderSell6,200$1.11$6,882.00View SEC Filing  
2/6/2017North Tide Capital, LlcMajor ShareholderSell28,027$1.10$30,829.70View SEC Filing  
2/3/2017North Tide Capital, LlcMajor ShareholderSell78,633$1.12$88,068.96View SEC Filing  
1/28/2017Santosh T VargheseInsiderSell429$1.11$476.19View SEC Filing  
12/31/2016Santosh T VargheseInsiderSell13,790$1.12$15,444.80View SEC Filing  
10/1/2016Santosh T VargheseInsiderSell710$1.14$809.40View SEC Filing  
8/2/2016Santosh T VargheseInsiderSell12,559$1.07$13,438.13View SEC Filing  
7/1/2016Santosh T VargheseVPSell366$1.21$442.86View SEC Filing  
4/7/2016Santosh T VargheseInsiderSell329$1.65$542.85View SEC Filing  
4/1/2016North Tide Capital, LlcMajor ShareholderBuy2,160$1.40$3,024.00View SEC Filing  
3/31/2016North Tide Capital, LlcMajor ShareholderBuy383,300$1.29$494,457.00View SEC Filing  
3/28/2016North Tide Capital, LlcMajor ShareholderBuy202,000$1.12$226,240.00View SEC Filing  
3/16/2016North Tide Capital, LlcMajor ShareholderBuy500,000$1.21$605,000.00View SEC Filing  
1/1/2016John L SlebirSVPSell2,973$3.04$9,037.92View SEC Filing  
1/8/2015North Tide Capital, LlcMajor ShareholderBuy500,000$3.12$1,560,000.00View SEC Filing  
1/6/2015North Tide Capital, LlcMajor ShareholderBuy476,800$3.04$1,449,472.00View SEC Filing  
1/2/2015North Tide Capital, LlcMajor ShareholderBuy523,200$2.90$1,517,280.00View SEC Filing  
3/11/2014Seth H.Z. FischerCEOBuy3,080$6.07$18,695.60View SEC Filing  
11/11/2013Alexander DennerDirectorBuy566,844$8.59$4,869,189.96View SEC Filing  
9/5/2013Timothy E MorrisCFOSell10,654$11.95$127,315.30View SEC Filing  
9/4/2013Michael J AstrueDirectorBuy10,000$11.96$119,600.00View SEC Filing  
6/27/2013Jon C BiroInsiderBuy2,000$12.85$25,700.00View SEC Filing  
5/29/2013Ernest MarioDirectorBuy15,000$14.68$220,200.00View SEC Filing  
8/20/2012Ernest MarioDirectorBuy5,000$20.75$103,750.00View SEC Filing  
8/10/2012Ernest MarioDirectorBuy20,000$21.74$434,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for VIVUS (NASDAQ:VVUS)
Latest Headlines for VIVUS (NASDAQ:VVUS)
DateHeadline logoZacks: Analysts Expect VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share - September 20 at 4:12 PM logoCritical Survey: VIVUS (VVUS) versus Its Rivals - September 18 at 2:26 AM logoVIVUS, Inc. (VVUS) Sees Large Drop in Short Interest - September 15 at 1:28 AM logoVIVUS (VVUS) Says Tacrolimus Received Orphan Drug Designation in the European Union for the Treatment of PAH - September 8 at 10:10 AM logoVIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis - September 8 at 10:10 AM logoVIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension - September 7 at 11:05 AM logoVIVUS (VVUS), Alvogen Announce Marketing Agreement for Qsymia in Republic of Korea - - September 6 at 10:09 AM logoVIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea - September 6 at 10:09 AM logoVIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound? - September 4 at 3:41 PM logoVIVUS (VVUS) and Alimera Sciences (ALIM) Head to Head Survey - September 2 at 10:24 PM logoVIVUS, Inc. (VVUS) Expected to Announce Earnings of -$0.13 Per Share - September 2 at 2:26 AM logoVIVUS, Inc. (VVUS) Downgraded by ValuEngine - September 2 at 12:06 AM logoVIVUS (VVUS) Settles with Dr. Reddy's Laboratories on Qsymia ... - - August 31 at 1:57 AM logoVIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation - August 30 at 8:54 PM logoVivid Potential Victory With Vivus, Inc. Convertible Bonds - Seeking Alpha - August 23 at 1:46 PM logoVIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017 - August 23 at 1:46 PM logoCritical Review: VIVUS (VVUS) & Tokai Pharmaceuticals (NVUS) - August 19 at 8:44 AM logoZacks: Brokerages Expect VIVUS, Inc. (NASDAQ:VVUS) to Post -$0.13 Earnings Per Share - August 14 at 2:30 PM logoVivus Pipeline Review, Analysis and Potential Catalysts - August 10 at 9:34 AM logoVIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y - Nasdaq - August 9 at 8:59 AM logoVIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y - August 8 at 8:15 AM logoPeregrine Pharmaceuticals (PPHM) & VIVUS (VVUS) Head-To-Head Analysis - August 5 at 8:36 PM logoVIVUS Reports Second Quarter 2017 Financial Results - August 3 at 4:34 PM logo-$0.13 EPS Expected for VIVUS, Inc. (NASDAQ:VVUS) This Quarter - July 27 at 11:17 AM logoZacks Investment Research Upgrades VIVUS, Inc. (VVUS) to "Buy" - July 27 at 10:14 AM logoVIVUS, Inc. (NASDAQ:VVUS) Set to Announce Earnings on Wednesday - July 26 at 7:48 AM logoVIVUS, Inc. (VVUS) Cut to "Hold" at Zacks Investment Research - July 19 at 12:38 PM logoVIVUS, Inc. (VVUS) Raised to "Buy" at Zacks Investment Research - July 17 at 2:52 PM logoVIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation - July 6 at 5:16 PM logoVIVUS, Inc. (NASDAQ:VVUS) Downgraded to "Hold" at Zacks Investment Research - July 4 at 1:07 PM logoVIVUS, Inc. (NASDAQ:VVUS) Expected to Announce Earnings of -$0.13 Per Share - July 3 at 10:14 AM logoShire's (SHPG) ADHD Drug Mydayis Receives Approval in US - June 22 at 2:38 PM logoMyriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7% - June 22 at 2:38 PM logoFibrocell Science (FCSC) Looks Good: Stock Moves Up 13.9% - June 20 at 9:09 AM logoInterpace Diagnostics Group, Inc. (IDXG) - June 17 at 7:13 AM logoCelgene (CELG) Reports Data on Lupus Drug in Phase II Trial - June 15 at 8:56 PM logoNovartis Presents Positive Data on CAR-T Cell Therapy Drug - June 12 at 8:04 PM logoVIVUS (VVUS) Shares March Higher, Can It Continue? - June 8 at 1:57 AM logoZacks: Brokerages Expect VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share - June 7 at 8:06 AM logoPerrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact - May 31 at 11:39 AM logoETFs with exposure to VIVUS, Inc. : May 30, 2017 - May 30 at 8:08 PM logoIntercept's (ICPT) Liver Drug Ocaliva Approved in Canada - May 29 at 3:33 PM logoVIVUS, Inc. :VVUS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017 - May 28 at 10:51 PM logoVIVUS (VVUS) Names Thomas King to Board of Directors - - May 26 at 8:31 AM logo5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio - - May 26 at 8:31 AM logo5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio - May 25 at 7:48 AM logoThomas B. King Joins VIVUS' Board of Directors - May 25 at 7:16 AM logoAstrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab - May 22 at 7:38 PM logoShire (SHPG) Up on Positive Phase III Study Data on HAE Drug - May 19 at 6:44 PM logoZacks: Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share - May 11 at 9:07 AM



VIVUS (VVUS) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff